Drugs for Skin Cancer
Here are the financial support services available to patients receiving treatment for Skin Cancer.
Bavencio (avelumab) Injection
Drug company: EMD Serono/Pfizer
Bavencio is a PD-L1 inhibitor used for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel-cell carcinoma, a type of skin cancer.
EMD Serono and Pfizer offer 2 financial assistance programs for patients using Bavencio:
CoverOne Co-Pay Assistance Program
Through this program, patients with private insurance will be responsible for a $0 copay at participating medical facilities and pharmacies, and may be eligible for copay assistance up to a maximum of $30,000 per year.
CoverOne Patient Assistance Program
This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.
Erivedge (vismodegib) Capsules
Drug company: Genentech
Erivedge is a hedgehog pathway inhibitor used for the treatment of patients with metastatic basal-cell carcinoma or locally advanced basal-cell carcinoma.
Genentech offers 2 financial assistance programs for patients using Erivedge:
Genentech BioOncology Coli-pay Card
For patients with insurance, the program ensures a $25 copay, with up to $25,000 provided annually. This program has no income requirements for participation.
Genentech Patient Foundation
This foundation provides Erivedge free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Erivedge is also provided free of charge for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.
Drug company: Merck
Keytruda is a PD-1 inhibitor used for the treatment of patients with recurrent locally advanced or metastatic Merkel-cell carcinoma, a type of skin cancer.
Merck offers 2 financial assistance programs for patients using Keytruda:
Merck Co-pay Assistance Program
Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income level up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.
Merck Patient Assistance Program
Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $60,700 or less for individuals, $82,300 or less for a couple, or $125,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.
Drug company: Regeneron/Sanofi Genzyme
Libtayo is a PD-1 inhibitor used for the treatment of patients with metastatic cutaneous squamous-cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery or radiation as a cure.
Regeneron and Sanofi Genzyme offer 2 financial assistance programs for patients who have been prescribed Libtayo:
Libtayo Surround Commercial Copay Program
Eligible patients who have private insurance may pay $0 for Libtayo, including copay, coinsurance, and insurance deductibles, with maximum assistance of $25,000 annually.
Libtayo Surround Patient Assistance Program
Patients who meet this program’s income requirements may receive Libtayo at no cost if they are uninsured, underinsured, or have Medicare Part B coverage with no supplemental insurance. To qualify for this program, patients must have an annual gross household income that does not exceed the greater of $100,000 or 500% of the federal poverty level.
Odomzo (sonidegib) Capsules
Drug company: Sun Pharma
Odomzo is a hedgehog pathway inhibitor used for the treatment of adults with locally advanced basal-cell carcinoma that has relapsed after surgery or radiation therapy, or in patients not candidates for surgery or radiation therapy.
Sun Pharma provides 2 financial assistance programs for patients using Odomzo:
Odomzo Copay Program
Patients with private insurance who are eligible for this program will pay as little as $10 per month for a prescription of Odomzo, with a maximum benefit of $15,000 a year.
Odomzo Patient Access Program
This program verifies the patient’s health insurance and out-of-pocket costs for Odomzo. Program coordinators will evaluate the patient’s eligibility for financial assistance based on certain medical and financial criteria.
Table. Drugs Prescribed for Skin Cancer
- Drug name (generic name)
- Drug company
- Patient support services
Drug name (generic name)
- Odomzo (sonidegib) Capsules
- Sun Pharma
- Locally advanced basal-cell carcinoma that relapsed after surgery or radiation or cannot be removed by surgery or radiation
Patient support services
- Odomzo Copay Program
Odomzo Patient Access Program
Last modified: February 11, 2019